Abstract
Preventative and therapeutic vaccines are increasingly used during pregnancy and present special considerations for developmental toxicity testing. The various components of the vaccine formulation (i.e., protein or polysaccharide antigen, adjuvants, and excipients) need to be assessed for direct effects on the developing conceptus. In addition, possible adverse influences of the induced antibodies on fetal and/or postnatal development need to be evaluated. A guidance document on the preclinical testing of preventative and therapeutic vaccines for developmental toxicity was issued by the FDA in 2006. Preclinical studies are designed to assess possible influences of vaccines on pre- and postnatal development. The choice of model animal for these experiments is influenced by species differences in the timing and extent of the transfer of the induced maternal antibodies to the fetus. The cross-placental transport of maternal immunoglobulins generally only occurs in late gestation and tends to be greater in humans and monkeys than in non-primate species. For many vaccines, the rabbit shows a greater rate of prenatal transfer of the induced antibodies than rodents. For biotechnology-derived vaccines that are not immunogenic in lower species, nonhuman primates may be the only appropriate models. It may be advisable to test new adjuvants using the ICH study designs for conventional pharmaceuticals in addition to the developmental toxicity study with the final vaccine formulation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Centers for Disease Control and Prevention (2009) Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 58:1–8
Raghupathy R (1997) Th1-type immunity is incompatible with successful pregnancy. Immunol Today 18:478–482
Verdier F, Barrow PC, Bruge J (2003) Reproductive toxicity testing of vaccines. Toxicology 185:213–219
Ryan MA, Gumbs GR, Conlin AM, Sevick CJ, Jacobson IG, Snell KJ, Spoone T, Smith TC (2008) Evaluation of preterm births and birth defects in liveborn infants of US military women who received smallpox vaccine. Birth Defects Res A Clin Mol Teratol 82:533–539
FDA (2006) Guidance for industry: considerations for developmental toxicity studies for preventive and therapeutic vaccines for infectious disease indications. http://www.fda.gov/ohrms/DOCKETS/98fr/E6-1998.htm. Accessed 16 Sept 2011
Barrow P (2011) Developmental and reproductive toxicity testing of vaccines. J Pharmacol Toxicol Methods 65(2):58–63. doi:10.1016/j.vascn.2011.12.001
ICH (2009) Draft consensus guideline. Addendum to ICH S6: preclinical safety evaluation of biotechnology-derived pharmaceuticals. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf. Accessed 16 Sept 2011
Pentsuk N, van der Laan JW (2009) An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 86:328–344
Barrow PC, Barbellion S, Stadler J (2010) Preclinical evaluation of juvenile toxicity. In: Gautier J-C (ed) Drug safety evaluation: methods and protocols. Humana Press, New York, pp 17–38
House RV, Selgrade MJ (2010) A quarter-century of immunotoxicology: looking back, looking forward. Toxicol Sci 118:1–3
Dietert RR, DeWitt J (2010) Developmental immunotoxicity (DIT): the why, when and how of DIT testing. In: Dietert RR (ed) Immunotoxicity testing: methods and protocols. Humana Press, New York, pp 17–26
EMEA (1997) Note for guidance on preclinical pharmacological and toxicological testing of vaccines. CPMP/SWP/465/95. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003102.pdf. Accessed 16 Sept 2011
ICH (2005) Harmonised tripartite guideline S5(R2). Detection of toxicity to reproduction for medicinal products & toxicity to male fertility. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S5_R2/Step4/S5_R2__Guideline.pdf. Accessed 16 Sept 2011
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Barrow, P.C., Allais, L. (2013). Developmental Toxicity Testing of Vaccines. In: Barrow, P. (eds) Teratogenicity Testing. Methods in Molecular Biology, vol 947. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-131-8_7
Download citation
DOI: https://doi.org/10.1007/978-1-62703-131-8_7
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-130-1
Online ISBN: 978-1-62703-131-8
eBook Packages: Springer Protocols